Table 1.
Summary of inferred MSI diagnoses from tumor exome sequencing.
| Cancer type (TCGA code)a | Fraction of Cases (Count) |
||
|---|---|---|---|
| MSS | Intermediate | MSI-H | |
| BLCA | 0.99 (375) | 0.01 (4) | 0 (0) |
| BRCA | 0.9 (866) | 0.04 (43) | 0.06 (53) |
| CESC | 0.97 (206) | 0.005 (1) | 0.02 (5) |
| CHOL | 0.98 (49) | 0 (0) | 0.02 (1) |
| COAD | 0.79 (309) | 0.02 (8) | 0.19 (74) |
| DLBC | 0.77 (36) | 0 (0) | 0.23 (11) |
| ESCA | 0.98 (145) | 0 (0) | 0.02 (3) |
| GBM | 0.95 (356) | 0.01 (4) | 0.04 (14) |
| HNSC | 0.99 (506) | 0.004 (2) | 0.01 (4) |
| KICH | 1 (64) | 0 (0) | 0 (0) |
| KIRC | 0.97 (321) | 0.02 (5) | 0.02 (5) |
| KIRP | 0.99 (248) | 0.004 (1) | 0.004 (1) |
| LAML | 0.92 (113) | 0.07 (8) | 0.02 (2) |
| LGG | 1 (494) | 0 (0) | 0.004 (2) |
| LIHC | 0.99 (329) | 0.003 (1) | 0.01 (4) |
| LUAD | 0.97 (525) | 0.01 (7) | 0.02 (10) |
| LUSC | 0.96 (436) | 0.01 (4) | 0.03 (12) |
| MESO | 0.98 (59) | 0.02 (1) | 0 (0) |
| OV | 0.87 (339) | 0.09 (34) | 0.05 (18) |
| PAAD | 1 (174) | 0 (0) | 0 (0) |
| PCPG | 1 (184) | 0 (0) | 0 (0) |
| PRAD | 0.99 (455) | 0 (0) | 0.01 (3) |
| READ | 0.94 (133) | 0.01 (2) | 0.05 (7) |
| SARC | 0.99 (186) | 0.01 (1) | 0.01 (1) |
| SKCM | 0.99 (439) | 0.005 (2) | 0.002 (1) |
| STAD | 0.79 (328) | 0.005 (2) | 0.2 (84) |
| TGCT | 1 (156) | 0 (0) | 0 (0) |
| THCA | 1 (454) | 0.002 (1) | 0 (0) |
| THYM | 0.99 (118) | 0 (0) | 0.01 (1) |
| UCEC | 0.57 (255) | 0.04 (17) | 0.4 (179) |
| UCS | 0.96 (55) | 0.02 (1) | 0.02 (1) |
| UVM | 1 (80) | 0 (0) | 0 (0) |
BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.